Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (91-100 of 266) with videos related to

Pageof 27
Sort By:
Journal of Clinical Medicine|January 13, 2019
Type 2 Diabetes Is Associated with a Different Pattern of Serum Polyamines: A Case⁻Control Study from the PREDIMED-Plus TrialJose C Fernandez-Garcia, Antoni Delpino-Rius, Iris Samarra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)Jonathan E Rosenberg, Se Hoon Park, Vadim Kozlov, et al.
Cancer Medicine|July 22, 2014
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCamillo Porta, Antonin Levy, Robert Hawkins, et al.
International Journal of Molecular Sciences|July 29, 2025
Exploring the Interplay Between Gut Microbiota and the Melatonergic Pathway in Hormone Receptor-Positive Breast CancerAurora Laborda-Illanes, Soukaina Boutriq, Lucía Aranega-Martín, et al.
Nature|November 18, 2024
Adipose tissue retains an epigenetic memory of obesity after weight lossLaura C Hinte, Daniel Castellano-Castillo, Adhideb Ghosh, et al.
European Urology Oncology|November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS TrialJoan Carles, Bertrand Tombal, Maha Hussain, et al.
Journal of Clinical Medicine|February 15, 2022
Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant ChemotherapyJuan Carlos Pardo, Tamara Sanhueza, Vicenç Ruiz de Porras, et al.
Journal of Clinical Lipidology|August 26, 2018
Differential effects of restrictive and malabsorptive bariatric surgery procedures on the serum lipidome in obese subjectsBruno Ramos-Molina, Daniel Castellano-Castillo, Juan Alcaide-Torres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trialGiorgio V Scagliotti, Cornelius Kortsik, Graham G Dark, et al.
BMC Cancer|September 24, 2013
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II studyMarta Martín-Richard, Bartomeu Massutí, Eva Pineda, et al.
Pageof 27

Showing results (91-100 of 266) with videos related to

Sort By:
Pageof 27
Journal of Clinical Medicine|January 13, 2019
Type 2 Diabetes Is Associated with a Different Pattern of Serum Polyamines: A Case⁻Control Study from the PREDIMED-Plus TrialJose C Fernandez-Garcia, Antoni Delpino-Rius, Iris Samarra, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 23, 2022
Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)Jonathan E Rosenberg, Se Hoon Park, Vadim Kozlov, et al.
Cancer Medicine|July 22, 2014
Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countriesCamillo Porta, Antonin Levy, Robert Hawkins, et al.
International Journal of Molecular Sciences|July 29, 2025
Exploring the Interplay Between Gut Microbiota and the Melatonergic Pathway in Hormone Receptor-Positive Breast CancerAurora Laborda-Illanes, Soukaina Boutriq, Lucía Aranega-Martín, et al.
Nature|November 18, 2024
Adipose tissue retains an epigenetic memory of obesity after weight lossLaura C Hinte, Daniel Castellano-Castillo, Adhideb Ghosh, et al.
European Urology Oncology|November 5, 2025
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS TrialJoan Carles, Bertrand Tombal, Maha Hussain, et al.
Journal of Clinical Medicine|February 15, 2022
Prognostic Impact of CD36 Immunohistochemical Expression in Patients with Muscle-Invasive Bladder Cancer Treated with Cystectomy and Adjuvant ChemotherapyJuan Carlos Pardo, Tamara Sanhueza, Vicenç Ruiz de Porras, et al.
Journal of Clinical Lipidology|August 26, 2018
Differential effects of restrictive and malabsorptive bariatric surgery procedures on the serum lipidome in obese subjectsBruno Ramos-Molina, Daniel Castellano-Castillo, Juan Alcaide-Torres, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trialGiorgio V Scagliotti, Cornelius Kortsik, Graham G Dark, et al.
BMC Cancer|September 24, 2013
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II studyMarta Martín-Richard, Bartomeu Massutí, Eva Pineda, et al.
Pageof 27